Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux

Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux

To the Editor: The Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial reported by Hoberman et al. (June 19 issue) 1 was similar to our Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts (PRIVENT) trial. 2 Despite...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2014-09, Vol.371 (11), p.1070-1073
Hauptverfasser: Craig, Jonathan C, Williams, Gabrielle J, Hodson, Elisabeth M, Roberts, Kenneth B, Hewitt, Ian, Dall'Amico, Roberto, Montini, Giovanni, Hari, Pankaj, Bagga, Arvind, Hoberman, Alejandro, Chesney, Russell W
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Infective Agents, Urinary - therapeutic use
Antibiotics
Children
Female
Humans
Male
Population studies
Prophylaxis
Recurrent infection
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
Urinary tract
Urinary tract diseases
Urinary tract infections
Urinary Tract Infections - prevention & control
Urogenital system
Vesico-Ureteral Reflux - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the Editor: The Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial reported by Hoberman et al. (June 19 issue) 1 was similar to our Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts (PRIVENT) trial. 2 Despite differences in the study populations of the PRIVENT trial and the RIVUR trial, the results were consistent (hazard ratio for the risk of recurrence of urinary tract infection, 0.61; 95% confidence interval [CI], 0.40 to 0.93 vs. 0.5; 95% CI, 0.34 to 0.74). In the RIVUR trial, 80 of 605 participants (13%) were lost to follow-up. This . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1408559